Bullish Case: Call volume leads puts by 50% and bullish risk is +21% across tenors while price holds near the $260 market-density mode. Nov 6 earnings IV spike (~88% market IV Nov 7) implies a priced catalyst; Scout 1.0's low-cost AI SRE agent and IBD record-high momentum support a beat-and-raise re-rate toward $275–290, with longer-dated IV (Jan/Sep '27 ~60%) cheap for upside carry.

Bearish Case: The stock just fell 8.1% from $283, breaking momentum after a parabolic 67% one-year run at 37.3x book. Nov 7 backwardated IV (Helium 102% at Nov 7 vs 58% Jan) prices heavy event risk; any deceleration in AI-linked NRR or guidance caution could retest the $225–235 density trough, and Helium's own forecast correlation (-0.1) argues against over-trusting bullish signals.

Potential Outcomes: 40% Beat + in-line guide: +4–8% to $270–282 by Dec (call skew, density peak $260–265). Falsified by two closes <$255.
25% Beat but cautious guide: +1–4% then IV bleed to $255–270.
20% Miss/weak guide: −10–15% to $220–235; put IV (Nov 180P at 93.8%) spikes.
10% M&A/Palo-Alto bid chatter rekindles: +12–20% toward $295+.
5% AI-disruption/competitive shock (Snowflake Observe): <$210.

October 20, 2026